Brought to you by 
Abbott to pay $56 in cash per share for Alere; terms amended to $51 per share
08 Sep 2020
Executive Summary
Abbott Laboratories Inc. is paying $56 per share (a 50% premium) or $5.8bn to acquire fellow public firm Alere Inc.
Deal Industry
- In Vitro Diagnostics
- Medical Devices
-
Pharmaceuticals
- Nutraceuticals
- OTC, Consumer
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Glucose Testing
- Urine-based Testing
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abbott to pay $56 in cash per share for Alere; terms amended to $51 per share
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice